EP0979652B1 - Composition curative de l'hypertension intraoculaire ou du glaucome - Google Patents
Composition curative de l'hypertension intraoculaire ou du glaucome Download PDFInfo
- Publication number
- EP0979652B1 EP0979652B1 EP98945530A EP98945530A EP0979652B1 EP 0979652 B1 EP0979652 B1 EP 0979652B1 EP 98945530 A EP98945530 A EP 98945530A EP 98945530 A EP98945530 A EP 98945530A EP 0979652 B1 EP0979652 B1 EP 0979652B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- latanoprost
- composition
- isopropyl unoprostone
- glaucoma
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the Present invention provides a composition for treatment of ocular hypertension or glaucoma.
- the invention provides a composition, which can enhance the effect of known compounds synergistically and can reduce the occurrence of unfavorable side effects.
- Isopropyl unoprostone (common name), a compound which is used as a component (a) of the present invention, is (+)-isopropyl-Z-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl] hept-5-enoate.
- An ocular hypotensive activity of this compound was described in EP-A-0308135 (corresponds to JP-A-02-108).
- Latanoprost (common name), a compound which is used as a component (b) of the present invention, is (+)-isopropyl-Z-7- ⁇ (1R, 2R, 3R, 5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl] cyclopentyl ⁇ -5-heptenoate.
- An ocular hypotensive activity of this compound was described in EP-A-0364417 (corresponds to JP-A-03-501025).
- any prior art does not teach the combined administration of the components (a) and (b) of the present invention, the effect may be increased synergistically, nor the adverse side effect may be reduced by the combination.
- An object of the present invention is to provide a composition for treatment of ocular hypertension or glaucoma, especially a composition which can provide a synergistic effect and reduce adverse side-effects.
- the present invention provides a composition useful for treatment of ocular hypertension or glaucoma comprising; (a) isopropyl unoprostone, and (b) Latanoprost.
- Isopropyl unoprostone (common name), the compound used for component (a), is (+)-isopropyl-Z-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl] hept-5-enoate.
- This compound has an ocular hypotensive activity, and different from natural PGs, does not induce transient increase of intraocular pressure. Therefore, the composition of the present invention may be applied for treatment of various diseases and conditions in which reduction of intraocular pressure is desired, for example, glaucoma, ocular hypertension and the other diseases accompanied by increased intraocular pressure.
- treatment or treating in this specification and claims refers to any means of control, including preventing or curing the disease, relieving or alleviating the condition, and arresting the development of the condition.
- Latanoprost (common name), the compound used for component (b) in the present invention, is (+)-isopropyl-Z-7- ⁇ (1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl] cyclopentyl ⁇ -5-heptenoate.
- This compound has been known to have an ocular hypotensive activity, and also to have some adverse side effects such as transient increase of intraocular pressure, hyperemia of conjunctiva, ocular irritation, and iris pigmentation.
- the combined administration of the component (a) and (b) provides a synergistic effect. That is, since the combination enhances the desired effects of each of the components (a) and (b) synergistically, the dose of the each component can be reduced, and therefore, adverse side effects of the each component can be effectively reduced.
- the ratio of (a): (b) is not limited but in general about 1:0.005-1:2, preferably, about 1:0.01-1.
- each component in the present composition may vary depending on state of the patient to be treated, severity of the condition, object of the treatment, diagnosis by a doctor, and total amount of administration.
- the amount of the component (a) in the composition is about 0.005-2 wt%, preferably, 0.01-1 wt%.
- the amount of the component (b) in the composition is about 0.0001-2 wt%, preferably, 0.0005-1 wt%.
- the components (a) and (b) may be administered either simultaneously or individually.
- composition of the present invention may be formulated to contain both of the components (a) and (b) in a single dosage unit, or may be a package consisting of separate dosage units containing each component respectively.
- the composition of the present invention may further contain any conventional compound used in ophthalmologic composition such as carrier and adjuvant.
- composition of the present invention may be formulated as liquids such as solution, emulsion, and suspension, or as semisolids such as gel or ophthalmic ointment.
- diluent for an aqueous solution or suspension examples include distilled water and physiological saline.
- diluent for a non-aqueous solution or suspension include vegetable oil, liquid paraffin, mineral oil, propylene glycol and p-octyldodecanol and the like.
- isotonic agents such as sodium chloride, boric acid and sodium citrate to make isotonic with the lacrimal fluid
- buffering agents such as borate buffer and phosphate buffer to maintain pH about 5.0 to 8.0 may be contained in the present composition.
- stabilizing agents such as sodium sulfite and propylene glycol, chelating agents such as sodium edetate, thickening agents such as glycerin, carboxymethyl cellulose and carboxyvinyl polymer, and preservatives such as methyl paraben, propyl paraben may be contained in the composition.
- the ingredients are sterilized by means of, for example, passing through a bacterial filter or heating.
- the ophthalmic ointment may contain, such as, vaseline, Zelen 50, Plastibase and Macrogol as base components and a surfactant for increasing hydrophilicity. Further, the composition may contain gelling agents such as carboxymethylcellulose, methylcellulose, carboxyvinyl polymer, as well.
- composition of the present invention may contain antibiotics such as chloramphenicol and penicillin, for preventing or treating bacterial infection.
- the present invention further provides the use of (a) isopropyl unoprostone and (b) Latanoprost for manufacturing a pharmaceutical composition for treatment of ocular hypertension or glaucoma.
- Latanoprost eye drops were administrated at 22 o'clock and then isopropyl unoprostone eye drops were administrated at 10 o'clock in the next morning, that is 12 hours after Latanoprost administration.
- the monkeys were anesthetized intramuscularly with 5.0-7.5 mg/kg of Ketamin (Sankyo Pharmaceuticals Co. Ltd.). A time course of the intraocular pressure was determined under topical anesthetization by dropping 0.4 % oxybuprocaine hydrochloride (Santen Pharmaceutical Co Ltd.) to eyes, by means of applanation pneumatonograph (Nippon Alcon).
- the present invention is useful for treatment of ocular hypertension or glaucoma.
Claims (6)
- Composition pour le traitement de l'hypertension oculaire ou du glaucome, comprenant (a) de l'isopropyle d'unoprostone et (b) du atanoprost.
- Composition selon la revendication 1, dans laquelle lesdits (a) isopropyle d'unoprostone et (b) atanoprost sont contenus dans une seule dose unitaire.
- Composition selon la revendication 1, dans laquelle lesdits (a) isopropyle d'unoprostone et (b) atanoprost sont respectivement contenus dans des doses unitaires distinctes.
- Utilisation de (a) isopropyle d'unoprostone et (b) atanoprost pour la fabrication d'une composition pharmaceutique pour le traitement de l'hypertension oculaire ou du glaucome.
- Utilisation selon la revendication 4, dans laquelle ladite composition pharmaceutique contient (a) de l'isopropyle d'unoprostone et (b) du atanoprost sous la forme d'une seule dose unitaire.
- Utilisation selon la revendication 4, dans laquelle ladite composition pharmaceutique contient (a) de l'isopropyle d'unoprostone et (b) du atanoprost sous la forme, respectivement, de doses unitaires distinctes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27854097 | 1997-10-13 | ||
JP27854097 | 1997-10-13 | ||
PCT/JP1998/004399 WO1999018969A1 (fr) | 1997-10-13 | 1998-09-30 | Composition curative de l'hypertension intraoculaire ou du glaucome |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0979652A1 EP0979652A1 (fr) | 2000-02-16 |
EP0979652A4 EP0979652A4 (fr) | 2003-05-14 |
EP0979652B1 true EP0979652B1 (fr) | 2006-05-24 |
Family
ID=17598695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98945530A Expired - Lifetime EP0979652B1 (fr) | 1997-10-13 | 1998-09-30 | Composition curative de l'hypertension intraoculaire ou du glaucome |
Country Status (9)
Country | Link |
---|---|
US (1) | US6329426B1 (fr) |
EP (1) | EP0979652B1 (fr) |
AT (1) | ATE326972T1 (fr) |
CA (1) | CA2274708A1 (fr) |
DE (1) | DE69834638T2 (fr) |
DK (1) | DK0979652T3 (fr) |
ES (1) | ES2265166T3 (fr) |
HK (1) | HK1024170A1 (fr) |
WO (1) | WO1999018969A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5011548B2 (ja) * | 1998-12-25 | 2012-08-29 | 株式会社アールテック・ウエノ | 高眼圧症あるいは緑内障の処置用医薬組成物 |
WO2002060387A2 (fr) * | 2001-01-30 | 2002-08-08 | Pharmaceutical Research Corporation | Utilisation d'analogues de prostaglandine dans le traitement d'etats cardiaques |
DE60326226D1 (de) * | 2002-03-21 | 2009-04-02 | Cayman Chemical Co | Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom |
WO2003082257A2 (fr) * | 2002-03-28 | 2003-10-09 | Sucampo Ag | Methode de traitement de l'hypertension oculaire et du glaucome |
US20020168424A1 (en) * | 2002-07-31 | 2002-11-14 | Dr. Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma |
US6864282B2 (en) | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
AR043161A1 (es) * | 2003-02-14 | 2005-07-20 | Sucampo Pharmaceuticals Inc | Composicion oftalmica para tratar hipertension ocular y glaucoma |
US7320871B2 (en) * | 2003-07-14 | 2008-01-22 | Allergan, Inc. | Human prostaglandin FP receptor variants and methods of using same |
CN103768070A (zh) * | 2006-03-13 | 2014-05-07 | 株式会社·R-技术上野 | 水性组合物 |
WO2008120249A1 (fr) * | 2007-03-30 | 2008-10-09 | Sifi S.P.A. | Produits pharmaceutiques à base de lipides polaires et non polaires pour utilisation ophtalmique |
EP2127638A1 (fr) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Procédé et composition pour traiter l'hypertension oculaire et le glaucome |
WO2017089980A1 (fr) * | 2015-11-26 | 2017-06-01 | Cadila Healthcare Limited | Doubles modulateurs de ppar pour le traitement de la rétinopathie diabétique et des maladies oculaires liées au diabète |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308135B1 (fr) | 1987-09-18 | 1992-11-19 | R-Tech Ueno Ltd. | Agents hypotenseurs ophtalmologiques |
ES2186670T3 (es) * | 1988-09-06 | 2003-05-16 | Pharmacia Ab | Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular. |
GB8916944D0 (en) | 1989-07-25 | 1989-09-13 | Ici Plc | Composite particle dispersions |
DE69232150T2 (de) * | 1992-03-19 | 2002-03-07 | R Tech Ueno Ltd | Behandlung von Augenhochdruck mit Betablockern und Prostansäurederivaten |
AU665287B2 (en) * | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
WO1997023225A1 (fr) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinaisons de prostaglandines de type dp et fp destinees a abaisser la pression intraoculaire |
-
1998
- 1998-09-30 ES ES98945530T patent/ES2265166T3/es not_active Expired - Lifetime
- 1998-09-30 EP EP98945530A patent/EP0979652B1/fr not_active Expired - Lifetime
- 1998-09-30 DE DE69834638T patent/DE69834638T2/de not_active Expired - Lifetime
- 1998-09-30 DK DK98945530T patent/DK0979652T3/da active
- 1998-09-30 AT AT98945530T patent/ATE326972T1/de not_active IP Right Cessation
- 1998-09-30 WO PCT/JP1998/004399 patent/WO1999018969A1/fr active IP Right Grant
- 1998-09-30 CA CA002274708A patent/CA2274708A1/fr not_active Withdrawn
- 1998-12-28 US US09/220,847 patent/US6329426B1/en not_active Expired - Lifetime
-
2000
- 2000-06-08 HK HK00103455A patent/HK1024170A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69834638T2 (de) | 2007-05-10 |
EP0979652A1 (fr) | 2000-02-16 |
ATE326972T1 (de) | 2006-06-15 |
CA2274708A1 (fr) | 1999-04-22 |
EP0979652A4 (fr) | 2003-05-14 |
WO1999018969A1 (fr) | 1999-04-22 |
DK0979652T3 (da) | 2006-09-11 |
DE69834638D1 (de) | 2006-06-29 |
US6329426B1 (en) | 2001-12-11 |
ES2265166T3 (es) | 2007-02-01 |
HK1024170A1 (en) | 2000-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3719609B2 (ja) | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 | |
EP0569046B1 (fr) | Dérivés de prostaglandine pour traitement du glaucome ou hypertension oculaire | |
US6225348B1 (en) | Method of treating macular degeneration with a prostaglandin derivative | |
US5891913A (en) | Ophthalmic and aural compositions containing diclofenac potassium | |
EP1541151B1 (fr) | Traitement contre le glaucome a base d'inhibiteurs de rho kinase et de prostaglandines | |
USRE39609E1 (en) | 8-iso-prostaglandins for glaucoma therapy | |
US4127674A (en) | Method of treatment for glaucoma | |
HU211835A9 (en) | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure | |
EP0979652B1 (fr) | Composition curative de l'hypertension intraoculaire ou du glaucome | |
US5614545A (en) | Topical composition for treatment of blepharitis | |
WO1993024121A1 (fr) | Medicament pour le glaucome | |
US10688113B2 (en) | Methods of treating eye pain with aminophosphinic derivatives | |
US5435998A (en) | Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents | |
US4197301A (en) | Topical ophthalmic use of Prazosin | |
US5527831A (en) | Pharmaceutical composition for topical application to the eye for treating increased intraocular pressure | |
EP0380560B1 (fr) | UTILISATION DE LA TETRACYCLINE POUR FABRIQUER UN MEDICAMENT DESTINè à DIMINUER LA PRESSION INTRAOCULAIRE | |
JPS6225645B2 (fr) | ||
US20040171681A1 (en) | Medicines and medicinal kits | |
EP1142576B1 (fr) | Compositions de medicament pour traiter l'hypertension oculaire ou le glaucome | |
US4188394A (en) | Ophthalmic composition and method of use | |
US4190673A (en) | Colchicine ophthalmic composition and method of use | |
EP1479387A1 (fr) | Remedes contre le glaucome contenant de la bunazosine et des prostaglandines | |
KR0124465B1 (ko) | 항녹내장성 안과용 조성물 | |
EP0375299A1 (fr) | Mélanges d'inhibiteurs ACE et CA pour le traitement du glaucome | |
EP0607697A2 (fr) | DILAZEP pour la réduction de la pression intraoculaire élevée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990618 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010608 |
|
17Q | First examination report despatched |
Effective date: 20040311 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 27/06 B Ipc: 7A 61K 31/557 A |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060524 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060524 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060524 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060524 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69834638 Country of ref document: DE Date of ref document: 20060629 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: R-TECH UENO, LTD. Free format text: R-TECH UENO, LTD.#4-8, KORAIBASHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0043 (JP) -TRANSFER TO- R-TECH UENO, LTD.#1-7, UCHISAIWAI-CHO 1-CHOME CHIYODA-KU#TOKYO-TO (JP) Ref country code: CH Ref legal event code: NV Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061002 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1024170 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061024 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2265166 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060825 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: R-TECH UENO, LTD. Free format text: R-TECH UENO, LTD.#1-7, UCHISAIWAI-CHO 1-CHOME CHIYODA-KU#TOKYO-TO (JP) -TRANSFER TO- R-TECH UENO, LTD.#1-7, UCHISAIWAI-CHO 1-CHOME CHIYODA-KU#TOKYO-TO (JP) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060524 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20140923 Year of fee payment: 17 Ref country code: DK Payment date: 20140919 Year of fee payment: 17 Ref country code: DE Payment date: 20140904 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20140814 Year of fee payment: 17 Ref country code: GB Payment date: 20140924 Year of fee payment: 17 Ref country code: SE Payment date: 20140911 Year of fee payment: 17 Ref country code: ES Payment date: 20140729 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20140930 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69834638 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20150930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20150930 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20151001 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20160531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160401 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151001 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151001 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150930 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20161026 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151001 |